http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102296346-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2020-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102296346-B1 |
| titleOfInvention | Application of α-synuclein for Diagnosing of Alzheimer's Disease and Improving Diagnosis of Alzheimer's Disease and Differential Diagnosis to Similar Degenerative Brain Diseases |
| abstract | The present invention relates to a method for diagnosing Alzheimer's disease using alpha-synuclein, and the method of the present invention experimentally confirmed the possibility of diagnosing Alzheimer's disease according to various biomarker combinations, increasing the diagnostic accuracy of Alzheimer's disease patients, Diagnosis with higher sensitivity is possible even in the early stages of the disease. In particular, through a specific biomarker combination (alpha-synuclein and tau), diagnosis of Alzheimer's disease is possible in patients with pathophysiologically suspected non-Alzheimer's disease (SNAP), and alpha- It can provide differentiated results from Lewy body dementia, Parkinson's disease, Parkinson's dementia, etc. in which synuclein is involved. |
| priorityDate | 2020-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 43.